Answers are grounded in this paper and cite their sources.
Cross-sectional study links dopamine biomarkers with cocaine addiction severity in individuals, suggesting potential for targeted treatment.
Introduction: Objective measures for severity of addiction are needed to identify and appropriately stratify patients into effective treatment groups for intervention and recovery. Our aim was to determine if blood-derived, dopamine-related biomarkers hold predictive validity in patients with cocaine use disorder. Methods: 349 participants [163 patients with moderate-to-severe cocaine use disorder (CUD), 186 healthy control participants without a history of substance use disorder] were recruited for a cross-sectional case-control study in the East of England, UK. Data on individual differences in cocaine use disorder-related traits, e.g., impulsivity, sensation-seeking, were collected. Measurements included mRNA transcription of dopamine-related genes (DRD2, DRD3, DRD4, and COMT) and risk alleles (rs6277, rs1800497, rs12364283, rs6280, and rs4680). Results: CUD patients showed elevated DRD2 mRNA in peripheral blood (B0=0.43, 95% CI [0.13, 0.73], pFDR=0.020) and the DRD2-related rs6277 risk allele was associated with CUD diagnosis (Odds ratio [OR]= 2.16, 95% CI [1.15, 4.17], p=0.02). DRD2 mRNA levels related to self-reported impulsivity (B0=−0.17, 95% CI [−0.32, −0.03], p=0.013). Conclusions: Blood-based expression of DRD2 may be a useful biomarker related to CUD diagnosis and related traits.
No takes yet. Share an insight, caveat, or question.
Kigar et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: